The world’s most important chip designers still depend on TSMC to manufacture their most advanced products.

BUSINESS ENGINE

Chip designers → TSMC manufactures advanced chips → Wafer revenue

The bet: Advanced computing keeps demanding more sophisticated chips, and TSMC keeps making the ones others cannot.

A toll road for the movement of money.

Mastercard benefits every time another transaction moves from cash to electronic payment or commerce crosses a border.

BUSINESS ENGINE

Electronic payments → Mastercard’s network and services → Transaction and service revenue

The bet: More of the world’s money moves electronically - and Mastercard earns a little more from moving it.

A biotechnology company that can fund its own ambition.

Vertex’s cystic-fibrosis dominance already produces substantial profits.

BUSINESS ENGINE

Cystic-fibrosis profits → New medicines and pipeline → Additional drug franchises

The bet: The existing franchise remains durable while even one of the next franchises becomes meaningful.

Elite underwriting at a distinctly unglamorous price.

Progressive has spent decades getting better at measuring and pricing risk. Its recent profitability will not remain at peak levels forever.

The stock no longer requires it to.

BUSINESS ENGINE

Insurance premiums → Better pricing of risk → Underwriting profit + investment income

The bet: Earnings normalize, but Progressive’s underwriting advantage does not.

Every da Vinci system placed inside a hospital expands an ecosystem of instruments, accessories and services tied to future procedures.

BUSINESS ENGINE

More da Vinci systems → More robotic procedures → Recurring instrument and service revenue

The bet: Robotic surgery keeps gaining ground, procedure volume keeps compounding and Intuitive remains the platform hospitals build around.

They are the five companies that earned capital.

Every member of the First Five enters with an argument for owning it, a price that makes the argument worthwhile - and a condition capable of getting it fired.

These are the full cases we are putting on the record.

Artificial intelligence has produced no shortage of beneficiaries. TSMC owns something more valuable than enthusiasm: the factories required to turn the industry’s most advanced designs into actual chips.

Second-quarter revenue reached $40.2 billion, while gross margin hit 67.7% and operating margin reached 60.3%. Management expects full-year 2026 revenue growth slightly above 40% in U.S.-dollar terms.

Those are software-like economics inside one of the most technically demanding manufacturing operations on Earth.

The risk cannot be buried in a spreadsheet. Most of the company’s advanced manufacturing remains concentrated in Taiwan. Semiconductor cycles, customer concentration and the higher cost of overseas factories matter too - but geopolitics is the risk capable of overwhelming everything else.

THE SEAT DEPENDS ON

Advanced computing continuing to demand more sophisticated chips - and TSMC remaining the manufacturer its largest customers cannot readily replace.

FIRED IF

Advanced-node utilization deteriorates beyond a normal semiconductor cycle; gross margins fall structurally below management’s long-term range; major customers successfully move leading-edge production elsewhere; or geopolitical developments push the position beyond the portfolio’s risk limit.

WHY IT WON

Vertiv and Fortinet offer attractive exposure to expanding digital infrastructure. TSMC owns the deeper bottleneck, produces stronger margins and asks less of its valuation.

Mastercard is often described as a tollbooth on global spending. That undersells it.

Second-quarter revenue rose 14% to $9.3 billion. Cross-border volume increased 12%, switched transactions grew 9%, and value-added services expanded roughly 20%.

The network remains the foundation. But fraud prevention, cybersecurity, authentication and data services allow Mastercard to earn more around each transaction—not merely process more of them. Combined with operating leverage and repurchases, that helped first-half diluted EPS rise 22%.

The company is easy to admire.

The stock requires more discipline.

At approximately 31.5 times trailing earnings, Mastercard must continue delivering low-teens revenue growth, faster earnings growth and resilient cross-border economics. This is not a valuation bargain. It is a wager that unusual consistency remains unusual.

THE SEAT DEPENDS ON

Electronic payments continuing to displace cash while Mastercard builds valuable services around the network it already operates.

FIRED IF

Currency-neutral revenue growth remains below high single digits for two quarters; cross-border volumes materially trail global travel; value-added services fall behind the core network without a credible explanation; or the stock remains above 30 times earnings while EPS growth approaches single digits.

WHY IT WON

Visa was the obvious challenger…and the larger network. Its latest quarter was formidable, with revenue up 14%, payments volume up 10% and cross-border volume up 13%.

Mastercard won on what happened after the revenue arrived. Adjusted operating income rose 16% and adjusted EPS increased 21%, compared with 11% adjusted-EPS growth at Visa. Its value-added services also expanded 20%.

Visa processes more of the world’s transactions. Mastercard is currently converting growth into earnings more effectively.

That narrower advantage earned the seat.

Vertex begins with something most biotechnology companies are still trying to create: a dominant, highly profitable franchise.

Its cystic-fibrosis medicines generated the earnings base behind second-quarter revenue of $3.33 billion, up 12%. Management raised full-year guidance to between $13.1 billion and $13.2 billion and expects at least $500 million of 2026 revenue from products outside cystic fibrosis.

That last number matters more than its size suggests.

Vertex does not need to replace its core franchise tomorrow. It needs to prove that cystic fibrosis can finance the creation of a second act. New products in pain and blood disorders have begun that test, with additional programs pursuing kidney disease and other large markets.

At approximately 28 times trailing earnings, the stock is not inexpensive. But the valuation does not require every clinical program to succeed, and Vertex can finance the work without repeatedly returning to shareholders for capital.

The danger is that drug development remains unforgiving. New launches can disappoint commercially, and one late-stage failure can erase years of expected value.

THE SEAT DEPENDS ON

The cystic-fibrosis franchise remaining durable while at least one new product line grows large enough to reduce the company’s dependence on it.

FIRED IF

The core franchise unexpectedly loses share or pricing power; products outside cystic fibrosis remain immaterial beyond 2027; a major late-stage failure leaves pipeline spending rising without a credible replacement; or acquisitions weaken the balance sheet without materially improving the pipeline.

WHY IT WON

Most biotechnology candidates asked the portfolio to accept either unproven economics or dependence on a narrow clinical outcome.

Vertex already possesses the profit engine required to fund several attempts at building its next franchise.

Intuitive Surgical earns money each time its installed platform is used. Vertex uses the profits from its established franchise to create new ones.

Both belong because they provide fundamentally different ways for healthcare innovation to compound.

Progressive’s recent earnings are almost certainly too strong to extrapolate forever.

That is not the thesis.

Second-quarter premiums earned increased 6% to $21.57 billion, policies in force grew 7%, and the combined ratio finished at a highly profitable 87.3. Quarterly EPS reached $5.67.

Growth has slowed, however, and June’s combined ratio deteriorated to 90.0 from 86.6 one year earlier. The insurance cycle is already moving away from perfection.

The interesting part is that the valuation knows it.

At approximately $211, Progressive traded near 10.6 times trailing earnings - one of the lowest multiples among the finalists. Those earnings sit above a conservative through-cycle estimate, but the price already allows for substantial normalization.

Progressive has spent decades becoming better at measuring and pricing risk. If that underwriting advantage survives, the company does not need to preserve peak profitability. It needs to remain better than the insurers competing for the same drivers.

Insurance can look wonderfully predictable right until yesterday’s assumptions receive tomorrow’s repair bill.

THE SEAT DEPENDS ON

Profitability normalizing without Progressive surrendering the underwriting and pricing advantage that produced it.

FIRED IF

The combined ratio exceeds 96 for two consecutive quarters without catastrophe distortion; policies decline while competitors gain share; or reserve development turns persistently adverse.

WHY IT WON

Chubb offers exceptional underwriting quality. Progressive narrowly won through faster policy growth and a lower multiple. If its auto-insurance advantage deteriorates, Chubb will be waiting.

Intuitive Surgical is commonly described as a medical-device company.

That misses the system around the machine.

Each da Vinci placement brings another hospital onto Intuitive’s platform. Each procedure then creates demand for instruments, accessories and service. Surgeons receive training on the system. Hospitals build operating rooms and workflows around it. Experience accumulates across the installed base.

The machine makes the first sale.

The ecosystem makes the next thousand harder to lose.

Second-quarter revenue increased 19% to $2.89 billion. Worldwide da Vinci procedures rose approximately 15%, while the installed base expanded 12% to 11,710 systems. Instruments-and-accessories revenue—the recurring engine attached to procedure volume—grew 18% to $1.73 billion.

Operating income rose 31%.

That combination matters. More systems are entering hospitals, more procedures are being performed on each generation of the platform, and earnings are growing faster than revenue.

The balance sheet adds protection. Intuitive ended the quarter with $8.63 billion in cash and investments, giving it substantial capacity to fund research, manufacturing and the continued rollout of da Vinci 5.

The difficult part is the price.

At approximately 43 times trailing earnings, Intuitive is the portfolio’s most demanding valuation. The company can continue growing and the stock can still disappoint if procedure growth slows or investors become less willing to pay for that growth.

This seat does not depend on robotic surgery being the future.

It depends on Intuitive continuing to own enough of that future to justify the price already attached to it.

THE SEAT DEPENDS ON

Robotic-assisted surgery continuing to gain adoption, procedure volume compounding at a double-digit rate and Intuitive converting its installed base into growing recurring revenue.

FIRED IF

Da Vinci procedure growth remains below 10% for two consecutive quarters without a temporary industry-wide cause; system placements and utilization weaken together; instruments-and-accessories revenue materially trails procedure growth; gross margins deteriorate structurally; or earnings growth falls toward single digits while the stock retains a premium valuation.

WHY IT WON

Intuitive combines double-digit procedure growth with an expanding installed base and recurring revenue that increases every time its systems are used.

That creates an unusually powerful compounding engine: more systems lead to more procedures, more procedures generate more instruments-and-accessories revenue, and every hospital built around the platform makes Intuitive harder to displace.

Other medical-device finalists offered attractive growth. Few matched Intuitive’s combination of market leadership, recurring economics, balance-sheet strength and earnings momentum.

The valuation leaves no room for complacency.

The business left very little room for anyone else.

That is the point of having only five seats.

The Bench contains the companies closest to changing the portfolio -not every stock that survived the research process. Each needs either stronger evidence, a better price or an incumbent to weaken.

Wabtec begins as the first Call-Up because it made the strongest case of any company left outside the portfolio.

Second-quarter sales rose 17.5%. Adjusted EPS increased 21.6%, adjusted operating margin reached 21.9%, and the multiyear backlog climbed to $30.93 billion. Management raised its full-year sales and earnings guidance.

Nothing about the quarter created the problem.

The price did.

At approximately 28 times adjusted earnings, Wabtec already carries substantial expectations. Acquisitions contributed to its recent growth, acquisition-related debt reduced its financial flexibility, and the stock leaves less room for execution to become merely good.

The business earned serious consideration.

The valuation kept it one place outside.

Wabtec does not need a particular company to fail.

It needs its operating strength to become more valuable than the price the market has already placed on it.

Chubb produced $7.26 of core operating earnings per share, an increase of 18.2%, while its property-and-casualty combined ratio reached an exceptional 83.8%.

At approximately 12 times trailing earnings, the valuation is difficult to fault. Progressive retained the insurance seat because it is growing policies faster at a slightly lower multiple.

Chubb is not far away. If Progressive’s auto-underwriting advantage weakens, this becomes a live contest.

ICE owns the sort of infrastructure Five Seats should like: exchanges, clearing operations and recurring data revenue tied to the plumbing of global finance.

The latest quarter was solid rather than decisive. Net revenue and adjusted EPS both grew 5%, leaving ICE cheaper than Mastercard but considerably slower.

Mastercard kept the financial-infrastructure seat because its stronger organic growth justified the higher price. ICE needs either an acceleration or a valuation gap too large to ignore.

Interactive Brokers continues to add accounts, client assets and commission revenue at an exceptional rate.

The obstacle is not execution. It is a valuation near 38 times trailing earnings attached to a business influenced by interest rates, market levels and trading activity.

The company has earned continued attention.

The stock has not yet earned 20%.

Constellation’s quarter moved it closer to a seat. Adjusted operating earnings rose from $1.91 to $2.55 per share, management raised full-year guidance, and new long-term nuclear agreements added visibility - but weaker fleet performance and the leverage and integration demands created by Calpine keep the case from becoming decisive.

Some will improve.
Some will become cheaper.
Some will make us regret leaving them outside.

That is what the Bench is for.

The First Five become official at Monday’s opening prices.

Each company will begin at an equal 20% weight. Those execution prices - and every result that follows - will be recorded permanently in the Five Seats Ledger alongside SPY and QQQ.

The research is finished.

Now the record begins.